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A B S T R A C T
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by highly variable distribution of tumor mass between
peripheral blood, bone marrow and lymphoid organs which is important for staging, classification and prognosis. These
clinical findings with novel data about importance of B-cell receptor and its stimulation with the support of micro-
environment indicate important role of tissues (lymphoid organs and bone marrow) in the pathogenesis of B-CLL. Here
is presented the novel approach of simultaneous characterization of B-CLL cells form peripheral blood, bone marrow
and lymph nodes by flow cytometry and immunocytochemistry, defining inter- and intraclonal diversity with respect to
various molecules. These include adhesion molecules (integrins, immunoglobulins, selectins), chemokine receptors (in-
cluding CXCR-4), signaling molecules and prognostic factors (CD38 and ZAP-70), proliferation and apoptosis markers
(including Ki67, AgNORs with PK index, survivin, bcl-2) and therapeutic targets (CD20 and CD52) and residual hema-
topoietic stem cells. A number of interesting significant interactions have been discovered, pointing to the important role
of neoplastic cell microenvironment. These may in addition to insights in pathogenesis and roles of different microenvi-
ronments add to diagnosis, prognosis and treatment of B-CLL patients.
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Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is a dis-
tinctive lymphoproliferative disorder characterized by
proliferation and accumulation of small monoclonal CD5
positive B-lymphocytes. These B-CLL lymphocytes traf-
fic between and home to a different sites resulting in
variable involvement of peripheral blood, bone marrow,
lymph nodes and spleen, as major lymphoid compart-
ments1. This is clinically translated into variable clinical
presentation ranging from pure leukemic forms (with
significant affection of peripheral blood and bone mar-
row only) to forms with significant affection of lymphoid
organs only i.e. small lymphocytic lymphoma (SLL),
while in majority of cases all lymphoid compartments are
involved covering whole range from mostly leukemic to
mostly lymphoma-like tumor distribution. The whole
spectrum is recognized by World Health Organization
(WHO) classification of lymphoid malignancies as the
same disease entity2. Beside heterogeneity regarding tu-
mor mass distribution and other distinctive clinical and
epidemiological characteristics (such as gender and age
distribution)3,4, one of the most important characteris-
tics is highly variable clinical course with numerous clin-
ical, hematologic, serum, cellular and molecular parame-
ters identified to be associated with prognosis5–9.
Current concepts about B-CLL pathogenesis point to
important role of B-cell receptor and antigen stimulation
as well as supporting tissue microenvironment1,10. On
the other side current requirements for B-CLL diagnosis
are relatively simple and reduced to demonstration of pe-
ripheral blood lymphocytosis with distinct clonal immu-
nophenotype (CD5+, CD23+, CD20dim, sIgMdim)11. B-CLL
research is also based predominantly on samples taken
from peripheral blood11. Well documented B-CLL intra-
309
Received for publication November 4, 2009
clonal variability in different lymphoid compartments12,13
question the concept of making clear conclusions about
pathogenetic processes occurring in tissue microenviron-
ment based on characteristics of malignant clone from
peripheral blood. It is also question whether documented
intraclonal differences regarding receptors and signaling
molecules can point to compartment specific events, cell
positioning and crosstalk as well as other microenvi-
ronmental influences.
In this review we will address the importance of tissue
compartments from clinical as well as biological point of
view. On examples of several key B-CLL receptors and
signaling molecules we will try to answer what can we
learn from lymph node and bone marrow: can informa-
tion obtained from lymph node and bone marrow sam-
ples provide additional knowledge about B-CLL patho-
genesis and can this information add to diagnosis, prog-
nosis and therapy?
Clinical Indicators of Lymph Node and
Bone Marrow Importance
Variable affection of lymphoid compartments beside
the historical importance in disease classification was
early recognized to have importance for prognosis. It is
in foundation of the first clinical staging system proposed
by Rai et al.14 that showed strong relationship with prog-
nosis. Its introduction revolutionized both clinical and
basic research providing the measure for various novel
findings. The basic idea behind this staging system is se-
quential affection of peripheral blood (stage 0), lymph
nodes (stage I), spleen and/or liver (stage II) and bone
marrow with cytopenias due to a level of infiltration
(stages III and IV). Although, today we know that this
concept of B-CLL progression is not valid since we deal
with practically systemic disease from the beginning due
to cell trafficking it has recognized two important factors
associated with prognosis. First is clinically recognizable
affection of lymphoid organs and second is bone marrow
failure – i.e. bone marrow infiltration leading to clinically
significant cytopenias.
Another major step forward was introduction of Total
tumor mass (TTM) score15. This scoring system has in-
troduced quantification of involvement of each lymphoid
compartment allowing to assess and monitor total tumor
burden during the course of the disease as well as to as-
sess response to therapy. Its usefulness in prognosis and
follow up was proved in numerous retrospective and pro-
spective clinical studies and clinical trials16–20. By quanti-
fying involvement of each lymphoid compartment, i.e.
peripheral blood/bone marrow, lymph node and spleen
this system also allows the quantification of tumor distri-
bution (TD) recognizing the spectrum form pure leuke-
mia to pure lymphoma and differentiation between pre-
dominantly leukemic to predominantly lymphoma like
cases9. It was also shown that TD has its independent
prognostic significance (worse prognosis of lymphoma
like cases) irrespective of total tumor burden as well as
unexpected relation to gender (being more significant in
females) and some other biological parameters21. It is
worth of noting that TTM scoring system doesn’t include
and it is independent of bone marrow failure.
Strong relationship of lymphoid organ and bone mar-
row involvement with prognosis may implicate their im-
portant role in pathogenesis of B-CLL. Quantitative and
more importantly qualitative differences in lymphoid
compartment affection indicate that site of B-CLL lym-
phocyte accumulation is important. Beside the major
principle valid in B-CLL and almost all malignancies
that more tumor load is associated with worse prognosis
and minor principle that tumor in certain locations is as-
sociated with poor prognosis (occurring rarely in B-CLL)
it can be speculated that predominant accumulation of
B-CLL lymphocytes in microenvironment favoring pro-
liferation and activation leads to a more active disease
and worse prognosis. Accumulation in (or spillover to)
peripheral blood which is relatively inert compartment
has a lesser independent influence on prognosis. What is
the biological background for these clinical observations?
B-cell Receptor and Tissue
Microenvironment
Classical morphological appearance of B-CLL inclu-
des small lymphocytes accumulating and infiltrating to a
variable extent to all lymphoid compartments including
peripheral blood, bone marrow and lymphoid organs22.
However, in lymphoid organs but also to a lesser degree
in bone marrow one of the histological hallmarks specific
to B-CLL are aggregates of larger cells (prolymphocytes
and paraimmunoblasts) with other cells (most notably T
cells) and supporting stroma22,23. These aggregates form
so called »pseudofollicles« resembling classical lymphoid
follicles which are the sites of B-cell activation by antigen
and T-cell help and proliferation. Pseudofollicules are the
presumed sites of proliferation in B-CLL24,25 and consti-
tute so-called »proliferation compartment« fueling so-
-called »accumulation compartment«. In this microenvi-
ronment there are number of interactions with other
cells (T-cells, stromal cells and accessory cells like nurse-
-like cells, etc.) and supporting stroma that provide other
important signals for B-CLL cells26. There are some indi-
cations that interactions with T-cells provide signals im-
portant for proliferation, while stromal and nurse-like
cells provide signals important for extended survival. A
number of receptors are involved in these interactions
including, CD40/CD40L, CD38, CXCR4/SDF-1, etc.27–32
(Figure 1).
Beside the resemblance of B-CLL proliferation cen-
ters to lymphoid follicles there is large amount of data in-
dicating important role of immune-mediated pathways
including B-cell receptor (BCR) and autoantigen stimu-
lation as well as supporting microenvironment in the
pathogenesis of B-CLL27,33. Important results came out
of studies of BCR including finding of highly restricted
and biased gene repertoire of immunoglobulin heavy
chain variable (IGHV) region compared to normal B-cell
repertoire34,35 and recognition of two groups of patients
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with different prognoses based on occurrence of somatic
mutations in this genes (mutated and unmutated)36,37.
Phenotypic38 and gene expression profiling39 signatures
also indicate that B-CLL cells are antigen experienced
cells. Signaling through BCR was found to be very impor-
tant for activation, proliferation and survival. Although
putative antigen stimulating BCR is unknown, B-CLL
cells produce polyreactive antibodies40 which are in a
number of cases autoantibodies thus suggesting some
kind of autoantigenes. All these findings are indicative
that antigenic pressure may be important for selection of
B-CLL cells, activation in T-cell dependent and T-cell in-
dependent manner and progression of the disease41. It is
currently unknown if it is important for disease induc-
tion.
What Can We Learn from Inter-
and Intraclonal Differences between
Compartments?
Current knowledge about B-CLL is predominantly
based on investigation of samples from peripheral blood
(accumulation compartment) and in vitro models, while
major pathogenetic processes take place in lymphoid or-
gans and bone marrow (proliferation compartment). In-
traclonal diversity, i.e. differences in B-CLL lymphocyte
characteristics depending on microenvironment (periph-
eral blood, lymph nodes and bone marrow) in single pa-
tient and its relation to other clinical and biological char-
acteristics may be related to patogenetic events in B-CLL
occurring in respective compartment. These events in-
clude trafficking and homing as well as activation,
proliferation and apoptosis. On the other side interclonal
diversity is defined as differences between different B-CLL
patients. To assess compartment specific phenotypic pro-
file and inter- and intraclonal diversities we have adop-
ted novel approach of simultaneous investigation of sam-
ples from different microenvironments, especially lymph
nodes and bone marrow compared to peripheral blood
with detailed phenotypic characterization B-CLL cells
with special emphasis on quantification. Major methods
involved were flow cytometry and immunocytochemistry
with image analysis. This approach uncovered novel data
as well as proved in vivo some hypothesis and in vitro
findings contributing to better characterization of molec-
ular mechanisms of B-CLL induction and progression.
Here is a brief review of our results covering adhesion
molecules and chemokine receptors, important signaling
molecules and prognostic factors CD38 and ZAP-70, cell
kinetics, markers of proliferation and apoptosis and re-
sidual hematopoietic stem cells.
Adhesion Molecules and
Chemokine Receptors
Our interest in B-CLL intraclonal diversity started
from interest in underlying mechanisms for cell traffick-
ing and homing which will provide biological basis and
explanation for variable tumor mass distribution in
B-CLL and its clinical significance. We have applied ap-
proach of simultaneous investigation of samples from pe-
ripheral blood, bone marrow and lymph nodes taken by
fine needle aspiration and detailed phenotypic character-
ization of a number of molecules on B-CLL lymphocytes.
Our panel consisted of extensive panel of adhesion mole-
cules including integrins, immunoglobulins, selectins,
CD44, and chemokine receptors including key CXCR-4
receptor. We have found different patterns of expression
for almost all adhesion molecules and chemokine recep-
tors between different compartments. Some of the mole-
cules showed higher expression in lymph nodes (like
CD54, b2 integrins, CD31), some showed higher expres-
sion in bone marrow while some showed higher expres-
sion in peripheral blood (like CXCR-4, CD102, CD44)42–44.
Also different molecules have different relationship with
a number of clinical and laboratory parameters indicat-
ing different roles in a multistep process of cell traffick-
ing and homing, as well as linking this process to patho-
genesis.
CD38 and ZAP-70
We have also evaluated CD38 and ZAP-70, key signal-
ing molecules and prognostic markers45–47. Both mole-
cules showed similar pattern of expression with the high-
est expression in lymph nodes and lowest in peripheral
blood12,48. These findings are in line with occurrence of
pseudofollicles in lymph nodes and bone marrow where
B-CLL cells receive multiple activating signals.
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Fig. 1. Role of peripheral blood, bone marrow and lymph node
microenvironment in regulation of balance between B-CLL acti-
vation/proliferation and apoptosis resistance/accumulation re-
sulting in progressive disease, stable disease or remission with
therapy. AG – antigen, C – Chemokine, cytokine milieu, T T-Cell,
FDC – follicular dendritic cell, NLC – nurse-like cell, M – ma-
crophage, E – endothelial cell, F – fibroblast.
CD20 and CD52
In recent years immunochemotherapy is gaining ground
in treatment of B-CLL patients showing improval of re-
sponse and survival rates49,50. Two monoclonal antibod-
ies are in wide use in the treatment of B-CLL, i.e.
rituximab (targeting CD20 molecule) and alemtuzumab
(targeting CD52 molecule). It is known that these anti-
bodies have different activity in different compartments
with rituximab mostly active in patients with lympha-
denopathy (with 11q deletion)51 and alemtuzumab highly
active in peripheral blood and bone marrow while rela-
tively ineffective in patients with bulky lymphadeno-
paty52,53. We have found relatively unexpected and con-
sistent different pattern of expression of CD20 and CD52
on B-CLL cells with CD20 showing highest expression in
peripheral blood and CD52 in lymph node compart-
ment54.
Proliferation and Apoptosis
We have studied by flow cytomety a proliferation
marker Ki-67 that show higher expression in B-CLL cells
from lymph nodes44. We have also studied a number of
molecules involved in cell cycle regulation and apoptosis
(including survivin, bcl-2, p53) that all showed higher ex-
pression in lymph nodes55. These results are also in line
with the presence of pseudofollicles in lymph nodes and
bone marrow which are presumed sites of proliferation
in B-CLL.
We have also analyzed cytologic smears from periph-
eral blood, bone marrow and lymph nodes by DNA image
cytometry and silver-stained nucleolar organizer regions
(Ag-NORs). Based on these parameters proliferative-ki-
netic index (PKI) was developed showing the strong rela-
tionship with prognosis56.
Residual Heamtopoeitic Stem Cells in
B-CLL
Although autologous stem cell transplantation cur-
rently is not a standard treatment option for B-CLL pa-
tients it may be effective and is under investigation57,58.
So we have investigated residual hematopoietic stem cell
compartment in B-CLL patients and also compared the
peripheral blood and bone marrow stem cells. We found
that older patients have fewer committed progenitors in
peripheral blood and that stem cells in BM show a more
evident inverse relationship with the size of the B-CLL
clone59.
Conclusions
B-CLL is systemic disease affecting all lymphoid com-
partments to a variable extent. In a view of well docu-
mented data suggesting importance of tissues in B-CLL,
peripheral blood sampling is clearly suboptimal. Sam-
pling of lymph nodes and bone marrow allow insight into
B-CLL intraclonal heterogeneity and better describe pro-
liferative and accumulative compartment and underly-
ing pathogenetic process. This may lead to new diagnos-
tic tools and may uncover novel therapeutic targets.
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KRONI^NA LIMFOCITNA LEUKEMIJA: UVIDI IZ LIMFNOG ^VORA I KO[TANE SR@I
I KLINI^KE PERSPEKTIVE
S A @ E T A K
B-stani~na kroni~na limfocitna leukemija (B-KLL) je obilje`ena izrazito varijabilnom raspodjelom tumorske mase
izme|u periferne krvi, ko{tane sr`i i limfnih organa, {to je zna~ajno odre|ivanje klini~kih stadija, klasifikaciju i prog-
nozu. Ovi klini~ke zna~ajke zajedno s novim nalazima o zna~aju B-stani~nog receptora i njegove stimulacije uz potporu
mikrookoli{a ukazuju na zna~ajnu ulogu tkiva (limfni organi i ko{tana sr`) u patogenezi B-KLL-a. Ovdje prikazujemo
novi pristup istodobnom karakterizacijom B-KLL stanica iz periferne krvi, ko{tane sr`i i limfnih ~vorova proto~nom
citometrijom i imunocitokemijom i definiranjem inter i intraklonalne raznolikosti obzirom na adhezijske molekule (in-
tegrine, imunoglobuline, selektine), kemokinske receptore (uklju~uju}i CXCR-4), signalne molekule i prognosti~ke
~imbenike (CD38 i ZAP-70), biljege povezane s kinetikom (Ki67, AgNOR, PK indeks), apoptozom (survivin, bcl-2),
lije~enjem (CD20, CD52) te rezidualne hematopoetske mati~ne stanice. Ovakav pristup osim uvida u patogenezu mo`e
doprinijeti dijagnozi, prognozi i lije~enju B-KLL bolesnika.
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